Insmed (INSM) Other Accumulated Expenses (2011 - 2026)
Insmed (INSM) posted quarterly Other Accumulated Expenses of $23.3 million for Q1 2026, up 112.86% year-over-year from $10.9 million in Q1 2025, and up 36.19% quarter-over-quarter from $17.1 million in Q4 2025.
Insmed (INSM) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Insmed's Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $23.3 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 112.86% year-over-year to $23.3 million; the TTM figure through Mar 2026 stood at $23.3 million (up 112.86% YoY), while the FY2025 annual figure was $17.1 million, up 170.41% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $23.3 million, up from $17.1 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $23.3 million in Q1 2026, with the low at $1.8 million in Q1 2023.
- The 5-year median for Other Accumulated Expenses is $6.5 million (2024), against an average of $8.2 million.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses decreased 29.23% in 2022, then surged 262.75% in 2024.
- Insmed's Other Accumulated Expenses stood at $4.7 million in 2022, then rose by 20.47% to $5.7 million in 2023, then rose by 11.46% to $6.3 million in 2024, then soared by 170.41% to $17.1 million in 2025, then surged by 36.19% to $23.3 million in 2026.
- Business Quant data shows INSM's Other Accumulated Expenses at $23.3 million in Q1 2026, $17.1 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.77 Mn |
| Mar 31, 2026 | 23.29 Mn |
| Dec 31, 2025 | 17.10 Mn |
| Sep 30, 2025 | 9.37 Mn |
| Jun 30, 2025 | 8.16 Mn |
| Mar 31, 2025 | 10.94 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 8.65 Mn |
| Mar 31, 2024 | 6.51 Mn |
| Dec 31, 2023 | 5.67 Mn |
| Sep 30, 2023 | 5.98 Mn |
| Jun 30, 2023 | 2.38 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 4.71 Mn |
| Sep 30, 2022 | 5.32 Mn |
| Dec 31, 2021 | 6.66 Mn |
| Mar 31, 2020 | 78,000.00 |
| Dec 31, 2019 | 280,000.00 |
| Sep 30, 2019 | 130,000.00 |